Active Movements: Akorn, Inc. (NASDAQ:AKRX), Parsley Energy Inc (NYSE:PE), Immuno Gen, Inc. (NASDAQ:IMGN), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

On Monday, Shares of Akorn, Inc. (NASDAQ:AKRX), lost -8.64% to $29.29.

Akorn, declared that it has launched the approved 30 mg strength of Myorisan(TM) (isotretinoin capsules, USP). This launch further builds the Myorisan(TM) product portfolio that also comprises 10 mg, 20 mg and 40 mg capsules.

Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, in addition to animal and over-the-counter (OTC) consumer health products in the United States and internationally.

Shares of Parsley Energy Inc (NYSE:PE), declined -4.17% to $14.03, during its last trading session.

Parsley Energy, declared that it will take part in the Johnson Rice 2015 Energy Conference in New Orleans on Tuesday, September 29, during which Bryan Sheffield, Chairman and Chief Executive Officer, is planned to make a presentation.

Parsley Energy, Inc., an independent oil and natural gas company, engages in the acquisition, development, production, exploration, and sale of crude oil and natural gas properties in the Permian Basin located in West Texas and Southeastern New Mexico.

At the end of Monday’s trade, Shares of Immuno Gen, Inc. (NASDAQ:IMGN), lost -3.26% to $10.10.

ImmunoGen, declared that investors, journalists and the general public are invited to listen to a live webcast of the Company’s analyst and investor event on September 18, 2015.

The event will focus on ImmunoGen’s strong foundation for growth, counting the advancement of its multi-product pipeline, its proprietary technology that is enabling the development of novel anticancer therapies and the Company’s core competencies that position it for success.

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Finally, Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), ended its last trade with -6.79% loss, and closed at $31.83.

ACADIA Pharmaceuticals, declared that it will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015, at 10:00 a.m. Eastern Time in New York City.

A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through October 13, 2015.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which accomplished the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has accomplished Phase II trial for the treatment of schizophrenia.

DISCLAIMER:

This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.

Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.

Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.

Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.

About Travis Garlick 1752 Articles
Been writing about and trading stocks since 2013. Manage a group of micro-cap investors on Facebook with over 15,000 members. Turned $8,500 into 185k the first year I started trading stocks and haven't looked back.